The average selling price for KINEMAX+ in Japan dropped in 2022, according to GlobalData. The average selling price, the complete price range of high and low prices and a 3-year forecast for the KINEMAX+ device in Japan can be viewed in GlobalData’s micro pricing report. Buy the report here.
Smarter leaders trust GlobalData
The KINEMAX+ is sold by Stryker Corp in the Stem/Femur market. Knee reconstruction is a surgical procedure involving the replacement of damaged or diseased parts of the knee joint. Stem/femur implants are used in primary, partial, and revision knee replacement procedures.
Factors contributing to the list price of a medical device include but are not limited to therapy area, complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. Moreover, final selling prices vary geographically and by facility type. These prices are further subject to discounts, as well as purchasing and distribution agreements.
For a complete picture of Stryker Corp’ Stem/Femur device pricing in Japan, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
This micro pricing report leverages GlobalData’s Global Brand Pricing tracker, which estimates brand-level selling prices (including discounts) of key medical devices in 30 countries. GlobalData’s Medical Intelligence Center uses a proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data. Medical device pricing data can be tracked by market, company, and brand globally.
